Author pages are created from data sourced from our academic publisher partnerships and public sources.
IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy
Hepatitis C virus (HCV) infects 3% of the world's population. Treatment of chronic HCV consists of a combination of PEGylated interferon-α (PEG-IFN-α) and ribavirin (RBV). To identify genetic… Expand
Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies.
A large number of studies have reported on spontaneous viral clearance rates in acute hepatitis C infection, however most have been small, and reported rates have varied quite widely. To improve the… Expand
Epidemiology and natural history of HCV infection
- B. Hajarizadeh, J. Grebely, G. Dore
- Nature Reviews Gastroenterology &Hepatology
- 1 September 2013
Worldwide, an estimated 130–170 million people have HCV infection. HCV prevalence is highest in Egypt at >10% of the general population and China has the most people with HCV (29.8 million).… Expand
Estimation of stage‐specific fibrosis progression rates in chronic hepatitis C virus infection: A meta‐analysis and meta‐regression
Published estimates of liver fibrosis progression in individuals with chronic hepatitis C virus (HCV) infection are heterogeneous. We aimed to estimate stage‐specific fibrosis progression rates and… Expand
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind,…
BACKGROUND Although the addition of the HCV NS3/4A protease inhibitors boceprevir and telaprevir to pegylated interferon (peginterferon) alfa plus ribavirin has improved sustained virological… Expand
Estimating progression to cirrhosis in chronic hepatitis C virus infection
To gain a clearer understanding of the rate of progression to cirrhosis and its determinants in chronic hepatitis C virus (HCV) infection, a systematic review of published epidemiologic studies that… Expand
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm.
The disease burden of hepatitis C virus (HCV) is expected to increase as the infected population ages. A modelling approach was used to estimate the total number of viremic infections, diagnosed,… Expand
NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome.
BACKGROUND & AIMS The efficacy of NS5A inhibitors for the treatment of patients chronically infected with hepatitis C virus (HCV) can be affected by the presence of NS5A resistance-associated… Expand
Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study
BACKGROUND Hepatitis B and hepatitis C virus infections are common causes of death related to liver disease. In this large study, we aimed to investigate all cause mortality of the viruses in a… Expand
Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States
- Soumitri Barua, R. Greenwald, J. Grebely, G. Dore, T. Swan, L. Taylor
- Annals of Internal Medicine
- 4 August 2015
Highly effective (cure rate >90%), once-daily, oral interferon-free treatments with minimal adverse effects are now available for hepatitis C virus (HCV) infection. Worldwide, an estimated 80 to 150… Expand